Abstract In spite of the significant advancements over the past fifty decades with regard to anticoagulant therapy, warfarin remains the definitive common for the very long-expression avoidance of thromboembolic situations in at-risk patients, except those with acute coronary syndromes, during which antiplatelets are most well-liked. Ximelagatran,

Article Under Review